Reliability of Her2/neu, estrogen receptor, and progesterone receptor testing by immunohistochemistry on cell block of FNA and serous effusions from patients with primary and metastatic breast carcinoma

2011 ◽  
Vol 39 (5) ◽  
pp. 328-332 ◽  
Author(s):  
Ahmed Shabaik ◽  
Grace Lin ◽  
Michael Peterson ◽  
Farnaz Hasteh ◽  
Ann Tipps ◽  
...  
Keyword(s):  
Estrogen Receptor ◽  
Breast Carcinoma ◽  
Progesterone Receptor ◽  
Metastatic Breast ◽  
Cell Block ◽  
Metastatic Breast Carcinoma

scholarly journals Cytologic assessment of estrogen receptor, progesterone receptor, and HER2 status in metastatic breast carcinoma

2017 ◽  
Vol 6 (1) ◽  
pp. 33-40 ◽  
Author(s):  
Fresia Pareja ◽  
Melissa P. Murray ◽  
Ryan Des Jean ◽  
Fumiko Konno ◽  
Maria Friedlander ◽  
...  
Keyword(s):  
Estrogen Receptor ◽  
Breast Carcinoma ◽  
Progesterone Receptor ◽  
Metastatic Breast ◽  
Her2 Status ◽  
Metastatic Breast Carcinoma

Determination of HER2/neu Status: A Pilot Study Comparing HER2/neu Dual In Situ Hybridization DNA Probe Cocktail Assay Performed on Cell Blocks to Immunohistochemisty and Fluorescence In Situ Hybridization Performed on Histologic Specimens

2014 ◽  
Vol 138 (4) ◽  
pp. 553-558 ◽  
Author(s):  
Adria K. Hartman ◽  
Blythe K. Gorman ◽  
Subhendu Chakraborty ◽  
Dina R. Mody ◽  
Mary R. Schwartz
Keyword(s):  
In Situ Hybridization ◽  
Breast Carcinoma ◽  
Fluorescence In Situ Hybridization ◽  
Gene Amplification ◽  
Biopsy Specimen ◽  
Metastatic Breast ◽  
Cell Block ◽  
Metastatic Breast Carcinoma ◽  
Resection Specimen

Context.—Validation of new methodologies for determining human epidermal growth factor receptor 2 gene (HER2/neu) amplification status is crucial for advancing the standard of care and determining treatment for patients with primary and/or metastatic breast carcinoma. Objective.—To compare results of HER2/neu gene amplification status by 2-color chromogenic in situ hybridization (ISH) on cell block material to HER2/neu status by immunohistochemistry (IHC) and/or fluorescence in situ hybridization (FISH) in the corresponding resection specimen or previous biopsy specimen. Design.—Formalin, thrombin, and Cellient cell blocks were prepared from cytologic samples obtained from resection specimens from 27 patients with invasive breast carcinoma. In situ hybridization was performed on cell block sections from 18 of the collected cases, on both the Ventana BenchMark ULTRA and the Ventana BenchMark XT, and the HER2/neu gene amplification status was determined. This was then compared to the HER2/neu status by IHC and/or FISH in the resection specimen or previous biopsy specimen. Results.—Comparison of HER2/neu status by ISH on the quantifiable cell block sections showed 100% correlation with the HER2/neu status determined by IHC or FISH in the corresponding histologic specimens. The results from thrombin and formalin cell blocks were statistically superior to the results from Cellient cell blocks on both Ventana instruments. Conclusions.—While further validation and study are needed, preliminary results show that the HER2/neu gene amplification status of breast carcinomas can reliably be determined on thrombin and formalin cell block material by using ISH. More consistent staining and better signal integrity was obtained with the Ventana BenchMark ULTRA than the BenchMark XT.

scholarly journals Comparison of GATA-3, mammaglobin, GCDFP-15 expression in breast carcinoma in serous effusions: A cell-block micro-array study

2017 ◽  
Vol 2 (3) ◽  
pp. 143-148
Author(s):  
Mohamed I. El Hag ◽  
Amani M. Hag ◽  
Jennifer P. Ha ◽  
Claire W. Michael
Keyword(s):  
Breast Cancer ◽  
Breast Carcinoma ◽  
Metastatic Breast ◽  
Cell Block ◽  
Chi Square ◽  
Metastatic Breast Carcinoma ◽  
Potential Marker ◽  
Er Positive ◽  
Micro Array ◽  
Cystic Disease Fluid Protein

AbstractBackgroundGATA-3 is a potential marker for detection of metastatic breast carcinoma, reportedly more sensitive than mammaglobin (MAM) and GCDFP-15. We aim to compare the sensitivity of GATA-3, MAM and GCDFP-15 in determining the breast origin of malignant effusions.MethodsCell blocks from 27 cases of serous effusions positive for metastatic breast cancer were retrieved. Immunohistochemistry for GATA-3, MAM, gross cystic disease fluid protein 15 (GCDFP-15), estrogen receptor (ER) and progesterone receptor (PR) was performed on cell-block micro-array. Statistical analysis using two ways Chi square, one-way ANOVA and multiple regression was performed.ResultsThe detection rate of breast cancer in serous fluid was significantly higher with GATA-3 (88.8 %, X2=15.9, p=0.00034) than with MAM (51.8 %) and GCDFP-15 (37.0 %). All ER positive cases (19) were GATA-3 positive. Conversely, all GATA-3 negative cases (3) were ER negative. The intensity of stain and percentage of positive cells were significantly higher with GATA-3 (p<0.0001) than with MAM and GCDFP-15. The intensity and percentage of positive cells score of GATA-3 were statistically associated with ER stain intensity and percentage of positive cell scores.ConclusionsGATA3 is a sensitive marker, superior to MAM and GCDFP-15 in determining the breast origin of metastatic adenocarcinoma. It is also strongly associated with ER expression.

The Utility of Estrogen Receptor and Progesterone Receptor Immunohistochemistry in the Distinction of Metastatic Breast Carcinoma From Other Tumors in the Liver

2003 ◽  
Vol 127 (12) ◽  
pp. 1591-1595 ◽  
Author(s):  
Jason W. Nash ◽  
Carl Morrison ◽  
Wendy L. Frankel
Keyword(s):  
Estrogen Receptor ◽  
Progesterone Receptor ◽  
Metastatic Breast ◽  
Metastatic Tumor ◽  
Breast Adenocarcinoma ◽  
Similar Frequency ◽  
Metastatic Breast Carcinoma ◽  
Pancreatic Metastases ◽  
Specificity And Sensitivity ◽  
Poorly Differentiated

Abstract Context.—The distinction of metastatic breast adenocarcinoma (MBA) to the liver from hepatocellular carcinoma (HCC), cholangiocarcinoma (CC), and metastatic adenocarcinoma from other sites may require the use of immunohistochemistry. The use of antibodies directed against estrogen receptor (ER) and progesterone receptor (PR) has been suggested to help make this distinction. Objective.—To examine the utility of ER and PR immunohistochemistry in the distinction of MBA from HCC, CC, and other metastatic adenocarcinomas in the liver. Methods.—Ninety-two previously characterized hepatic neoplasms were identified, including HCC (n = 14), CC (n = 16), and metastatic tumors from breast (n = 17), colorectal (n = 14), pancreatic (n = 15), and esophageal/gastric (n = 16) origins. For all cases of metastatic tumor, the primary tumor was reviewed to verify the diagnosis. All tumors were graded as well, moderately, or poorly differentiated. Estrogen receptor and PR immunohistochemical staining was performed on all cases and evaluated by 2 pathologists. Results.—Immunoreactivity for ER was identified only in MBA, with 6 (35%) of 17 cases positive. Positive immunoreactivity for PR was not restricted to MBA, but was seen in HCC, CC, esophageal/gastric, and pancreatic metastases. Positive immunostaining with PR was nearly as frequent in poorly differentiated carcinomas of nonbreast origin (3/16 cases, 19%) as in poorly differentiated breast carcinomas (2/8 cases, 25%). Conclusion.—Progesterone receptor exhibited poor specificity and sensitivity for the distinction of MBA from HCC, CC, and other metastatic adenocarcinomas. Estrogen receptor exhibited poor sensitivity for MBA, although the specificity was good. The finding that PR positivity was present with a similar frequency in poorly differentiated tumors of breast and nonbreast origin limits the usefulness of this marker. Therefore, ER and PR staining have limited utility in the distinction of MBA from HCC, CC, and other metastatic adenocarcinomas in the liver.

scholarly journals MMP9 EXPRESSION IN THE CYTOPLASM OF SURROUNDING STROMAL CELLS OF BREAST CARCINOMA IN RELATION TO PATHOLOGICAL STAGE, GRADE AND RECEPTOR STATUS

2021 ◽  
pp. 1-3
Author(s):  
Priyanka Saha ◽  
Sandipan Banik ◽  
Anadi Roy Chowdhury ◽  
Tushar Kanti Das ◽  
Debarshi Jana
Keyword(s):  
Breast Cancer ◽  
Estrogen Receptor ◽  
Breast Carcinoma ◽  
Progesterone Receptor ◽  
Early Stage ◽  
Metastatic Breast ◽  
The United States ◽  
Receptor Expression ◽  
Cross Sectional ◽  
Her 2

INTRODUCTION Breast cancer is the most common malignancy and the second leading cause of cancer-related death after lung cancer among women in the United States and Europe. Due to major advances in screening and early diagnostic procedures, most breast cancer patients are diagnosed at an early stage. However, 6% to 10% of patients still present with metastatic breast cancer at the time of diagnosis; for those patients, relapses tend to occur earlier and survival rates are shortened. AIMS AND OBJECTIVES To study MMP 9, Estrogen receptor, Progesterone receptor and Her-2-Neu expression in breast carcinoma by immune histochemistry. Compare MMP 9 expression with result of Estrogen receptor expression, Progesterone receptor expression and Her-2-Neu expression in breast carcinoma. To study MMP 9 expression in relation to staging and grading of breast cancer. MATERIALS AND METHOD This cross-sectional study was conducted on a group of patients admitted in Department of General Surgery, R G Kar Medical College & Hospital, Kolkata from January 2018 - Jun 2019. Approval from an institutional review board was obtained at the initiation of the study. All patients were provided with signed informed written consent. Cross sectional, descriptive and observational. RESULTS AND PUBLICATION From the above table it is evident that only 2 of the patients with stage II tumor showed MMP9 positivity while 8 were negative, but in case of patients with stage III disease 20 out of 22 showed MMP9 positivity with only 2 of them showing a negative MMP9 pattern. From the above table it is evident that only 1 out of 6 cases with grade 1 breast cancer was positive for MMP9 , while 11 out of 16 cases of grade 2 disease showed MMP9 positivity and all cases with grade 3 was found to be MMP9 positive. The above table clearly shows that out of 12 ER positive breast cancer cases only one third i.e. 4 were MMP9 positive. However, out of 20 ER negative cases 90% i.e. 18 were found to be MMP9 positive.

Sign in / Sign up

Export Citation Format

Share Document